Trial Condition(s):

Papulopustular Rosacea

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

Bayer Identifier:

14428

ClinicalTrials.gov Identifier:

NCT00417937

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.

Inclusion Criteria
- Papulopustular facial rosacea; minimum of 10, maximum of 50 inflamed papules and/or pustules
Exclusion Criteria
- Mild or severe rosacea
- Rosacea with marked ocular manifestations
- Presence of dermatoses that could interfere with the rosacea diagnosis or evaluation of the study course
- Wash out period required for patients treated prior to study with topical retinoids, oral antibiotics, topical antibiotics, systemic and topical corticosteroids, topical imidazole, laser surgery for telangiectasia
- History of hypersensitivity to propylene glycol

Trial Summary

Enrollment Goal
98
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Finacea (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Intendis GmbH

Berlin, Germany

Status
Completed
 

Trial Design